Lipid-lowering agent - Revision history

Fire at 01:24, 16 April 2024

2024-04-16T01:24:58Z

← Older revision		Revision as of 10:24, 16 April 2024
Line 17:		Line 17:
	\|販売		\|販売
	\|[[Takeda Pharmaceutical Company]]		\|[[Takeda Pharmaceutical Company]]
			\|
			\|-
			\|[[Ethyl eicosapentaenoic acid/ja]]
			\|[https://med.mochida.co.jp/medicaldomain/circulatory/epadel/index.html エパデール](持田製薬) ([https://med.mochida.co.jp/txt/pdf/epa-s_n22.pdf PI]) ([https://med.mochida.co.jp/interview/epas_n22.pdf IF])
			\|販売
			\|[[Mochida Pharmaceutical]]
	\|		\|
	\|-		\|-

Fire at 13:55, 15 April 2024

2024-04-15T13:55:34Z

@@ Line 1: / Line 1: @@
 {| class="wikitable sortable" style="width:100%"
 |+脂質降下薬（その他）
@@ Line 15: / Line 20: @@
 |-
 |}
 '''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.

Fire at 13:54, 15 April 2024

2024-04-15T13:54:37Z

← Older revision		Revision as of 22:54, 15 April 2024
Line 12:		Line 12:
	\|販売		\|販売
	\|[[Takeda Pharmaceutical Company]]		\|[[Takeda Pharmaceutical Company]]
			\|
	\|-		\|-
	\|}		\|}

Fire at 13:54, 15 April 2024

2024-04-15T13:54:12Z

← Older revision		Revision as of 22:54, 15 April 2024
Line 1:		Line 1:
			{\| class="wikitable sortable" style="width:100%"
			\|+脂質降下薬（その他）
			\|-
			!一般名
			!先発名
			!class="unsortable"\| 日本
			!創薬/開発
			!備考
			\|-
			\|[[Omega-3 acid ethyl esters/ja]]
			\|[https://www.takedamed.com/medicine/detail?medicine_id=601 ロトリガ](武田薬品) ([https://pins.japic.or.jp/pdf/newPINS/00060775.pdf PI]) ([https://www.takedamed.com/medicine/detail?medicine_id=601&setpopflage=true IF])
			\|販売
			\|[[Takeda Pharmaceutical Company]]
			\|-
			\|}
	<languages />		<languages />
	<translate>		<translate>

Fire at 05:58, 15 April 2024

2024-04-15T05:58:01Z

← Older revision		Revision as of 14:58, 15 April 2024
Line 2:		Line 2:
	<translate>		<translate>
	<!--T:1-->		<!--T:1-->
			{{Drug List/ja}}
	{{PathNav\|Medication\|frame=1}}		{{PathNav\|Medication\|frame=1}}
	'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology\|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.		'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology\|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.

Fire at 05:53, 15 April 2024

2024-04-15T05:53:12Z

← Older revision		Revision as of 14:53, 15 April 2024
Line 2:		Line 2:
	<translate>		<translate>
	<!--T:1-->		<!--T:1-->
	{{PathNav\|Medication}}		{{PathNav\|Medication\|frame=1}}
	'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology\|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.		'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology\|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.

Fire at 05:53, 15 April 2024

2024-04-15T05:53:00Z

← Older revision		Revision as of 14:53, 15 April 2024
Line 2:		Line 2:
	<translate>		<translate>
	<!--T:1-->		<!--T:1-->
			{{PathNav\|Medication}}
	'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology\|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.		'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology\|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.

Fire: Marked this version for translation

2024-04-13T12:44:40Z

Marked this version for translation

← Older revision		Revision as of 21:44, 13 April 2024
Line 1:		Line 1:
	<languages />		<languages />
	<translate>		<translate>
			<!--T:1-->
	'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology\|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.		'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology\|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.

	== Classes ==		== Classes == <!--T:2-->

			<!--T:3-->
	The several classes of lipid lowering drugs may differ in both their impact on the cholesterol profile and adverse effects. For example, some may lower [[low density lipoprotein]] (LDL) levels more so than others, while others may preferentially increase [[high density lipoprotein]] (HDL). Clinically, the choice of an agent depends on the patient's [[cholesterol\|cholesterol profile]], [https://web.archive.org/web/20060511202743/http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof cardiovascular risk], and the [[Liver function test\|liver]] and [[Creatinine clearance\|kidney]] functions of the patient, evaluated against the balancing of risks and benefits of the medications. In the United States, this is guided by the [[evidence-based medicine\|evidence-based]] guideline most recently updated in 2018 by the [[American College of Cardiology]] & [[American Heart Association]].		The several classes of lipid lowering drugs may differ in both their impact on the cholesterol profile and adverse effects. For example, some may lower [[low density lipoprotein]] (LDL) levels more so than others, while others may preferentially increase [[high density lipoprotein]] (HDL). Clinically, the choice of an agent depends on the patient's [[cholesterol\|cholesterol profile]], [https://web.archive.org/web/20060511202743/http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof cardiovascular risk], and the [[Liver function test\|liver]] and [[Creatinine clearance\|kidney]] functions of the patient, evaluated against the balancing of risks and benefits of the medications. In the United States, this is guided by the [[evidence-based medicine\|evidence-based]] guideline most recently updated in 2018 by the [[American College of Cardiology]] & [[American Heart Association]].

			<!--T:4-->
	===Established===		===Established===
	* [[Statin]]s (HMG-CoA reductase inhibitors) are particularly well suited for lowering LDL, the cholesterol with the strongest links to vascular diseases. In studies using standard doses, statins have been found to lower LDL-C by 18% to 55%, depending on the specific statin being used. A risk exists of muscle damage ([[myopathy]] and [[rhabdomyolysis]]) with statins. Hypercholesterolemia is not a risk factor for mortality in persons older than 70 years and risks from statin drugs are more increased after age 85.		* [[Statin]]s (HMG-CoA reductase inhibitors) are particularly well suited for lowering LDL, the cholesterol with the strongest links to vascular diseases. In studies using standard doses, statins have been found to lower LDL-C by 18% to 55%, depending on the specific statin being used. A risk exists of muscle damage ([[myopathy]] and [[rhabdomyolysis]]) with statins. Hypercholesterolemia is not a risk factor for mortality in persons older than 70 years and risks from statin drugs are more increased after age 85.
Line 17:		Line 20:
	* [[Probucol]] (withdrawn in several countries)		* [[Probucol]] (withdrawn in several countries)

	=== Alternative ===		=== Alternative === <!--T:5-->

			<!--T:6-->
	* [[Lecithin]] has been shown to effectively decrease cholesterol concentration by 33%, lower LDL by 38% and increase HDL by 46%.		* [[Lecithin]] has been shown to effectively decrease cholesterol concentration by 33%, lower LDL by 38% and increase HDL by 46%.
	* [[Phytosterol]]s may be found naturally in plants. Similar to ezetimibe, phytosterols reduce the absorption of cholesterol in the gut, so they are most effective when consumed with meals. However, their precise mechanism of action differs from ezetimibe.		* [[Phytosterol]]s may be found naturally in plants. Similar to ezetimibe, phytosterols reduce the absorption of cholesterol in the gut, so they are most effective when consumed with meals. However, their precise mechanism of action differs from ezetimibe.
Line 30:		Line 34:
	* [[Flaxseed oil]]		* [[Flaxseed oil]]

			<!--T:7-->
	==Research==		==Research==
	Investigational classes of hypolipidemic agents:		Investigational classes of hypolipidemic agents:
Line 39:		Line 44:
	* [[Bempedoic acid]], an ATP citrate lyase inhibitor		* [[Bempedoic acid]], an ATP citrate lyase inhibitor

			<!--T:8-->
	==See also==		==See also==
	* [[ATC code C10]]		* [[ATC code C10]]

			<!--T:9-->
	{{Major Drug Groups}}		{{Major Drug Groups}}
	{{Lipid modifying agents}}		{{Lipid modifying agents}}

			<!--T:10-->
	{{二次利用\|date=19 February 2024}}		{{二次利用\|date=19 February 2024}}
	[[Category:Hypolipidemic agents]]		[[Category:Hypolipidemic agents]]
	</translate>		</translate>

Fire at 12:43, 13 April 2024

2024-04-13T12:43:29Z

← Older revision		Revision as of 21:43, 13 April 2024
Line 1:		Line 1:
			<languages />
			<translate>
	'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology\|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.		'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology\|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.

Line 45:		Line 47:
	{{二次利用\|date=19 February 2024}}		{{二次利用\|date=19 February 2024}}
	[[Category:Hypolipidemic agents]]		[[Category:Hypolipidemic agents]]
			</translate>

Fire: Created page with "'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic..."

2024-04-13T12:40:01Z

Created page with "'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic..."

New page

'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.

== Classes ==

The several classes of lipid lowering drugs may differ in both their impact on the cholesterol profile and adverse effects. For example, some may lower [[low density lipoprotein]] (LDL) levels more so than others, while others may preferentially increase [[high density lipoprotein]] (HDL). Clinically, the choice of an agent depends on the patient's [[cholesterol|cholesterol profile]], [https://web.archive.org/web/20060511202743/http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof cardiovascular risk], and the [[Liver function test|liver]] and [[Creatinine clearance|kidney]] functions of the patient, evaluated against the balancing of risks and benefits of the medications. In the United States, this is guided by the [[evidence-based medicine|evidence-based]] guideline most recently updated in 2018 by the [[American College of Cardiology]] & [[American Heart Association]].

===Established===
* [[Statin]]s (HMG-CoA reductase inhibitors) are particularly well suited for lowering LDL, the cholesterol with the strongest links to vascular diseases. In studies using standard doses, statins have been found to lower LDL-C by 18% to 55%, depending on the specific statin being used. A risk exists of muscle damage ([[myopathy]] and [[rhabdomyolysis]]) with statins. Hypercholesterolemia is not a risk factor for mortality in persons older than 70 years and risks from statin drugs are more increased after age 85.
* [[Fibrate]]s are indicated for [[hypertriglyceridemia]]. Fibrates typically lower triglycerides by 20% to 50%. Level of the good cholesterol HDL is also increased. Fibrates may decrease LDL, though generally to a lesser degree than statins. Similar to statins, the risk of muscle damage exists.
* [[Niacin (medication)|Niacin]], like fibrates, is also well suited for lowering triglycerides by 20–50%. It may also lower LDL by 5–25% and increase HDL by 15–35%. Niacin may cause [[hyperglycemia]] and may also cause [[hepatotoxicity|liver damage]]. The niacin derivative [[acipimox]] is also associated with a modest decrease in LDL.
* [[Bile acid sequestrant]]s (resins, e.g. cholestyramine) are particularly effective for lowering LDL-C by sequestering the cholesterol-containing bile acids released into the intestine and preventing their reabsorption from the intestine. It decreases LDL by 15–30% and raises HDL by 3–5%, with little effect on triglycerides, but can cause a slight increase. Bile acid sequestrants may cause gastrointestinal problems and may also reduce the absorption of other drugs and vitamins from the gut.
* [[Ezetimibe]] is a selective inhibitor of dietary cholesterol absorption.
* [[Lomitapide]] is a [[microsomal triglyceride transfer protein]] inhibitor.
* [[PCSK9]] inhibitors are [[monoclonal antibody|monoclonal antibodies]] for refractory cases. (e.g. [[Evolocumab]], [[Inclisiran]]) They are used in combination with [[statin]]s.
* [[Probucol]] (withdrawn in several countries)

=== Alternative ===

* [[Lecithin]] has been shown to effectively decrease cholesterol concentration by 33%, lower LDL by 38% and increase HDL by 46%.
* [[Phytosterol]]s may be found naturally in plants. Similar to ezetimibe, phytosterols reduce the absorption of cholesterol in the gut, so they are most effective when consumed with meals. However, their precise mechanism of action differs from ezetimibe.
* [[Omega-3 fatty acid|Omega-3]] supplements taken at high doses can reduce levels of triglycerides. They are associated with a very modest increase in LDL (~5%).
* [[Choline]]
* [[Pycnogenol]]
* [[Berberine]]
* [[Red yeast rice]] is the natural source from which statins were discovered, but the FDA currently disallows any RYR with significant amounts of statin to be sold as a dietary supplement
* [[Boswellia serrata]]
* [[L-arginine]] may enhance the effects of a Statin, but will not lead to a reduction in cholesterol alone.
* [[Flaxseed oil]]

==Research==
Investigational classes of hypolipidemic agents:
* [[CETP inhibitor]]s (cholesteryl ester transfer protein), 1 candidate is in trials. ([[Anacetrapib]]) It is expected that these drugs will mainly increase HDL while lowering LDL
* [[Squalene synthase inhibitor]]
* [[ApoA-1 Milano]]
* Succinobucol (AGI-1067), a novel antioxidant, failed a phase-III trial.
* Apoprotein-B inhibitor [[mipomersen]] (approved by the FDA in 2013 homozygous [[familial hypercholesterolemia]].).
* [[Bempedoic acid]], an ATP citrate lyase inhibitor

==See also==
* [[ATC code C10]]

{{Major Drug Groups}}
{{Lipid modifying agents}}

{{二次利用|date=19 February 2024}}
[[Category:Hypolipidemic agents]]